Location of Repository

Variation in the Haemostatic Response and Thrombotic Risk: Interplay between Haemostatic Factors, Platelets and Monocytes

By Joy Rhiannon Wright

Abstract

The haemostatic response comprises the interaction of coagulation factors and peripheral blood cells which play a vital role in maintaining vascular integrity. This study begins with the finding that plasma from premature MI subjects has increased endogenous thrombotic potential linked to higher levels of circulating Tissue Factor (TF), suggesting these individuals may have a hypercoagulable phenotype. This study seeks to further understand how cellular interaction, in particular platelet-monocyte interaction, modulates the haemostatic response. Throughout the study, TF and Tissue Factor Pathway Inhibitor (TFPI) were studied as representing the procoagulant and anticoagulant response, respectively. \ud Study of the effects of activated platelets on monocytes found that whereas direct platelet or platelet-microparticle adhesion to monocytes, and release of platelet soluble mediators induced monocyte gene expression of TF, induction of TFPI was driven solely by platelet soluble mediators. Extension of these studies using gene expression microarray technology found that whereas activation of monocytes via PSGL-1 generates a pro-angiogenic expression profile, platelet soluble mediators significantly enhanced this profile, enabling monocytes to interact with ECM components involved in the wound healing environment of the thrombus, and additionally induced anti-inflammatory, and anti-atherothrombotic genes. \ud Whether cells within a thrombus act simply as structural and secretory components, or play a more active role involving gene expression is unclear, therefore gene expression array analysis was carried out on thrombi generated in vitro. Genes demonstrating significant time-dependent increases included those encoding chemotactic proteins (IL8, CCL2, CXCL1, CXCL2), cell adhesion (ITGAV, ITGA5, ITGB1), regulation of coagulation (THBD, PLAU, SERPINE1), wound-healing (ENDG, SPP1, LAMB3), and regulatory transcription factors (FOS, EGR1, PPARG). Whereas initiation of thrombosis is driven by plasma proteins and facilitated by the platelet surface, this study provides evidence that thrombus resolution may be driven by changes in gene expression within the thrombus that regulate the haemostatic response, thrombus growth, and facilitate wound-healing. These findings could have implications for individuals at risk of plaque rupture, where variation in gene expression may affect not just the formation of an occlusive thrombus but also the rate of resolution

Publisher: University of Leicester
Year: 2010
OAI identifier: oai:lra.le.ac.uk:2381/10075

Suggested articles

Preview

Citations

  1. (2007). [Novel imaging techniques for quantifying overall atherosclerotic burden].
  2. (2007). [Vascular injury by glucocorticoid; involvement of apoptosis of endothelial cells].
  3. (1998). 455G/A polymorphism of the beta-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men: proposed role for an acute-phase reaction pattern of fibrinogen.
  4. (2001). A cell-based model of hemostasis.
  5. (1997). A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women.
  6. (1986). A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes.
  7. (2008). A critical role for extracellular protein disulfide isomerase during thrombus formation in mice.
  8. (1998). A dual thrombin receptor system for platelet activation.
  9. (2006). A GPI-anchored co-receptor for tissue factor pathway inhibitor controls its intracellular trafficking and cell surface expression.
  10. (2009). A HaemAtlas: characterizing gene expression in differentiated human blood cells.
  11. (1989). A macrophage receptor that recognizes oxidised low density lipoprotein but not acetylated low density lipoprotein.
  12. (1998). A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis.
  13. (1985). A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation.
  14. (2001). A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis.
  15. (2002). A prospective study of venous thromboembolism in relation to factor V Leiden and related factors.
  16. (2005). A rich chemokine environment strongly enhances leukocyte migration and activities.
  17. (1959). A study of artificial thrombi produced by a modification of Chandler's method.
  18. (2002). Abnormal vascular function and hypertension in mice deficient in estrogen receptor beta.
  19. (2003). Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin.
  20. (2002). Activated platelets but not endothelial cells participate in the initiation of the consolidation phase of blood coagulation.
  21. (1989). Activated platelets express IL-1 activity.
  22. (1993). Activated platelets induce endothelial secretion of interleukin-8 in vitro via an interleukin-1-mediated event.
  23. (1996). Activated platelets signal chemokine synthesis by human monocytes.
  24. (2005). Activated protein C induces the release of microparticle-associated endothelial protein C receptor.
  25. (2009). Activating transcription factor 3 constitutes a negative feedback mechanism that attenuates saturated Fatty acid/toll-like receptor 4 signaling and macrophage activation in obese adipose tissue.
  26. (2002). Activation markers of coagulation and fibrinolysis in twins: heritability of the prethrombotic state.
  27. (1991). Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces.
  28. (1999). activation of human plataelets by thrombin.
  29. (2006). Activation of platelet function through G-Protein coupled receptors.
  30. (2001). Activation of the TGF-beta/activin-Smad2 pathway during allergic airway inflammation.
  31. (1996). Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1.
  32. (2007). Active tissue factor pathway inhibitor is expressed on the surface of coated platelets.
  33. (1994). ADP causes partial degranulation of platelets in the absence of aggregation.
  34. (2000). ADP is not an agonist at P2X(1) receptors: evidence for separate receptors stimulated by ATP and ADP on human platelets.
  35. (1990). Alpha-granule pool of glycoprotein IIb-IIIa in normal and pathologic platelets and megakaryocytes.
  36. (2000). alpha-granule secretion in platelets.
  37. (2005). Alterations in myocardial tissue factor expression and cellular localization in dilated cardiomyopathy.
  38. (2006). Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis.
  39. (2008). Altered fibrin clot structure and function in the healthy first-degree relatives of subjects with intermittent claudication.
  40. (2002). Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease.
  41. (2007). Alternatively spliced human tissue factor (asHTF) is not pro-coagulant.
  42. (2007). Alternatively spliced human tissue factor promotes tumor growth and angiogenesis in a pancreatic cancer tumor model. Thromb Res,
  43. (2003). Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein.
  44. (2009). Alternatively spliced tissue factor induces angiogenesis through integrin ligation.
  45. (1990). Amplified RNA synthesized from limited quantities of heterogeneous cDNA.
  46. (1964). An Enzyme Cascade in the Blood Clotting Mechanism, and Its Function as a Biochemical Amplifier.
  47. (2005). Analysis of gene and protein expression during monocyte-macrophage differentiation and cholesterol loading--cDNA and protein array study.
  48. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T
  49. (2003). Analysis of TF gene polymorphism 4.2.2.1. Allele Frequency
  50. (1987). Angiogenesis from mononuclear cells in thrombi. Virchows Arch A Pathol Anat Histopathol,
  51. (2008). Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released.
  52. (1987). Arginyl-glycyl-aspartic acid sequences and fibrinogen binding to platelets.
  53. (2001). Association between dietary patterns and plasma biomarkers of obesity and cardiovascular disease risk.
  54. (1998). Association of fibrinogen, Creactive protein, albumin, or leukocyte count with coronary heart disease: metaanalyses of prospective studies.
  55. (2008). Association of peroxisome proliferator-activated receptorgamma gene Pro12Ala and C161T polymorphisms with metabolic syndrome.
  56. (1998). Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction--the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction.
  57. (1991). Atherosclerotic plaque caps are locally weakened when macrophages density is increased.
  58. (1996). Beta fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. The ECTIM Study. Etude Cas-Temoins sur l'Infarctus du Myocarde.
  59. (2001). Beta-fibrinogen gene -455G/A polymorphism and coronary heart disease incidence: the Atherosclerosis Risk in Communities (ARIC)
  60. (1996). Beta-fibrinogen gene-455 G/A polymorphism and fibrinogen levels. Risk factors for coronary artery disease in subjects with NIDDM.
  61. (2009). Betaadrenergic signaling regulates NR4A nuclear receptor and metabolic gene expression in multiple tissues.
  62. (2002). Biochemical properties of platelet microparticle membranes formed during exocytosis resemble organelles more than plasma membrane.
  63. (2008). Blood clotting reactions on nanoscale phospholipid bilayers. Thromb Res,
  64. (1990). Blood platelet formation in vitro. The role of the cytoskeleton in megakaryocyte fragmentation.
  65. (1999). Blood platelets are assembled principally at the ends of proplatelet processes produced by differentiated megakaryocytes.
  66. (1993). Blood viscosity, fibrinogen, and activation of coagulation and leukocytes in peripheral arterial disease and the normal population in the Edinburgh Artery Study.
  67. (1999). Blood-borne tissue factor: another view of thrombosis.
  68. (2003). Bone marrow monocyte lineage cells adhere on injured endothelium in a monocyte chemoattractant protein-1-dependent manner and accelerate reendothelialization as endothelial progenitor cells.
  69. (2001). C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis.
  70. (2001). C/EBPbeta phosphorylation by RSK creates a functional XEXD caspase inhibitory box critical for cell survival.
  71. (2006). C/EBPbeta regulates TNF induced MnSOD expression and protection against apoptosis.
  72. (2007). Calcium ionophore-induced de-encryption of tissue factor in monocytes is associated with extensive cell death.
  73. (2009). Calibrated automated thrombin generation in paediatric patients with inflammatory bowel disease.
  74. (2009). CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization.
  75. (1990). CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein.
  76. (2004). CD14+CD16+ monocytes in coronary artery disease and their relationship to serum TNF-alpha levels.
  77. (1998). CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells.
  78. (2001). CD40-mediated signaling in monocytic cells: up-regulation of tumor necrosis factor receptor-associated factor mRNAs and activation of mitogen-activated protein kinase signaling pathways.
  79. (2005). CD44 is a physiological E-selectin ligand on neutrophils.
  80. (2001). Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation.
  81. (1997). Cell-derived microparticles generated in patients during cardiopulmonary bypass are highly procoagulant.
  82. (1999). Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture.
  83. (2000). Cellular origin and procoagulant properties of microparticles in meningococcal sepsis.
  84. (2007). Cellular origins and thrombogenic activity of microparticles isolated from human atherosclerotic plaques.
  85. (2000). Cerebral venous thrombosis and the G20210A mutation of factor II.
  86. (1994). Changes in clot deformability--a possible explanation for the epidemiological association between plasma fibrinogen concentration and myocardial infarction.
  87. (1962). Changes in the activity of clotting factors in relation to the onset of platelet clumping and fibrin formation.
  88. (1995). Characterization of protein disulphide isomerase released from activated platelets.
  89. (2004). Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis.
  90. (2006). Circulating CD31+/annexin V+ apoptotic microparticles correlate with coronary endothelial function in patients with coronary artery disease.
  91. (2001). Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction.
  92. (2007). Circulating platelet-derived microparticles are associated with atherothrombotic events: a marker for vulnerable blood.
  93. (2004). Clinical measurement of thrombin generation by calibrated automated thrombography requires contact factor inhibition.
  94. (1992). Cloned platelet thrombin receptor is necessary for thrombin-induced platelet activation.
  95. (1977). Clotting factors and platelets. Immunofluorescence evidence that fibrinogen and factor VIII are present in human washed platelets, whereas prothrombin complex factors and factor XIII are lacking.
  96. (1998). Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation.
  97. (1981). Coagulation factor III (tissue factor) interaction with phospholipid vesicles induced by cadmium: characterization of the reconstituted protein-membrane complex.
  98. (2008). Coagulation factors and the protein C system as determinants of thrombin generation in a normal population.
  99. (2009). Coagulopathy by hypothermia and acidosis: mechanisms of thrombin generation and fibrinogen availability.
  100. (1999). Coexpression of tissue factor and tissue factor pathway inhibitor by human monocytes purified by leukapheresis and elutriation. Response of nonadherent cells to lipopolysaccharide.
  101. (1999). Collagen-platelet interaction: Gly-Pro-Hyp is uniquely specific for platelet Gp VI and mediates platelet activation by collagen.
  102. (1991). Comparison of anticoagulant and procoagulant activities of stimulated platelets and platelet-derived microparticles.
  103. (2005). Comparison of cell-surface TFPIalpha and beta.
  104. (1976). Comparison of the coagulant activities of platelets and phospholipids.
  105. (1988). Complement proteins C5b9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity.
  106. (1989). Complete sequence of the human tissue factor gene, a highly regulated cellular receptor that initiates the coagulation protease cascade.
  107. (2008). Computational study on effect of red blood cells on primary thrombus formation.
  108. (1975). Concanavalin A inhibits tissue factor coagulant activity.
  109. (2002). Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux.
  110. (2005). Conditional knockout of macrophage PPARgamma increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice.
  111. (1997). Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets.
  112. (1999). Contribution of erythrocytes to thrombin generation in whole blood.
  113. (2000). Contribution of monocytes/macrophages to compensatory neovascularization: the drilling of metalloelastase-positive tunnels in ischemic myocardium.
  114. (2003). Control of thrombus embolization and fibronectin internalization by integrin alpha IIb beta 3 engagement of the fibrinogen gamma chain.
  115. (2008). Corn trypsin inhibitor in fluorogenic thrombin-generation measurements is only necessary at low tissue factor concentrations and influences the relationship between factor VIII coagulant activity and thrombogram parameters.
  116. (1989). Coronary risk associated with age and sex of parental heart disease in the Framingham Study.
  117. (1994). Correlation between inhibition of cytoskeleton proteolysis and anti-vesiculation effect of calpeptin during A23187-induced activation of human platelets: are vesicles shed by filopod fragmentation?
  118. (2008). Critical cap thickness and rupture in symptomatic carotid plaques: the oxford plaque study.
  119. (2005). Critical roles of Raf/MEK/ERK and PI3K/AKT signaling and inactivation of p38 MAP kinase in the differentiation and survival of monocyte-derived immature dendritic cells.
  120. (1994). Crystal structure of the extracellular region of human tissue factor.
  121. (1983). Cultured human endothelial cells generate tissue factor in response to endotoxin.
  122. (1990). Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis.
  123. (2000). Cytokine and intracellular signaling regulation of tissue factor expression in astrocytes.
  124. (2005). Defective thrombus formation in mice lacking coagulation factor XII.
  125. (2001). Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis.
  126. (1987). Deregulated c-fos expression interferes with normal bone development in transgenic mice.
  127. (1980). Determination of acid hydrolases in human platelets.
  128. (2002). Development of platelet secretory granules.
  129. (1993). Development of storage granules during megakaryocyte maturation: accumulation of adenine nucleotides and the capacity for serotonin sequestration.
  130. (2005). diabetes-related traits in UK samples.
  131. (2009). Different functions of monocyte subsets in familial hypercholesterolemia: potential function of CD14+ CD16+ monocytes in detoxification of oxidized LDL.
  132. (2000). Differential chemokine receptor expression and function in human monocyte subpopulations.
  133. (1996). Differential cytokine expression in human blood monocyte subpopulations: a polymerase chain reaction analysis.
  134. (1992). Differential expression of cytokines in human blood monocyte subpopulations.
  135. (2009). Differential stimulation of monocytic cells results in distinct populations of microparticles.
  136. (1973). Differentiation of human monocytes in bone marrow and blood. Sequential formation of two granule populations.
  137. (2005). Discrepancy between tissue factor activity and tissue factor expression in endotoxin-induced monocytes is associated with apoptosis and necrosis.
  138. (1986). Distribution of blood monocytes between a marginating and a circulating pool.
  139. (1993). Distribution of tissue factor pathway inhibitor in normal and malignant human tissues.
  140. (2006). Disulfide isomerization switches tissue factor from coagulation to cell signaling.
  141. (2006). Diverse physiological functions for dualspecificity MAP kinase phosphatases.
  142. (2005). During coagulation, thrombin generation shifts from chemical to diffusional control.
  143. (2003). Dynamic changes of fibrin architecture during fibrin formation and intrinsic fibrinolysis of fibrin-rich clots.
  144. (1991). Dynamics of leukocyte-platelet adhesion in whole blood.
  145. (2008). Early growth response gene 2 (Egr-2) controls the self-tolerance of T cells and prevents the development of lupuslike autoimmune disease.
  146. (2009). Effect of burn injury on apoptosis and expression of apoptosis-related genes/proteins in skeletal muscles of rats.
  147. (2003). Effect of unfractionated heparin and a low molecular weight heparin (enoxaparin) on coagulant activity of cultured human endothelial cells.
  148. (2005). Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice.
  149. (2003). Effects of severe hypertension on endothelial and platelet microparticles.
  150. (2003). Egr-1 target genes in human endothelial cells identified by microarray analysis.
  151. (2000). Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes.
  152. (2003). Elevated prothrombin results in clots with an altered fiber structure: a possible mechanism of the increased thrombotic risk.
  153. (2009). Endogenous thrombin potential (ETP) in plasma from patients with AMI during antithrombotic treatment.
  154. (2000). Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress.
  155. (2005). Endothelial KLF2 links local arterial shear stress levels to the expression of vascular tone-regulating genes.
  156. (2005). Endothelial microparticles induce formation of platelet aggregates via a von Willebrand factor/ristocetin dependent pathway, rendering them resistant to dissociation.
  157. (2007). Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA.
  158. (2005). Eph kinases and ephrins support thrombus growth and stability by regulating integrin outside-in signaling in platelets.
  159. (1994). Erythroid cell-specific determinants of alphaglobin mRNA stability.
  160. (2005). Escaping the nuclear confines: signal-dependent pre-mRNA splicing in anucleate platelets.
  161. (2009). Estrogen and mechanisms of vascular protection.
  162. (2002). Estrogen modulation of endothelial nitric oxide synthase.
  163. (2005). Evidence for a granule targeting sequence within platelet factor 4.
  164. (2006). Evidence for activation of tissue factor by an allosteric disulfide bond.
  165. (1999). Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques.
  166. (1989). Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man.
  167. (1999). Evidence for two distinct G-protein coupled ADP receptors mediating platelet activation.
  168. (2007). Evidence that differential packaging of the major platelet granule proteins von Willebrand factor and fibrinogen can support their differential release.
  169. (1993). Expression cloning of a functional glycoprotein ligand for P-selectin.
  170. (1994). Expression of a paternal history of premature myocardial infarction on fibrinogen, factor VIIC and PAI1 in European offspring--the EARS study.
  171. (1996). Expression of the alpha(1,3)fucosyltransferase Fuc-TVII in lymphoid aggregate high endothelial venules correlates with expression of L-selectin ligands.
  172. (1988). Expression of tissue factor and factor VIIa/tissue factor inhibitor activity in endotoxin or phorbol ester stimulated U937 monocyte-like cells.
  173. (1994). Expression of tissue factor and tissue factor pathway inhibitor in monocytes in response to bacterial lipopolysaccharide and phorbolester.
  174. (2008). Expression of tissue factor pathway inhibitor by endothelial cells and platelets.
  175. (1998). Expression of tissue factor pathway inhibitor in vascular smooth muscle cells and its regulation by growth factors.
  176. (1990). Expression of tissue factor procoagulant activity: regulation by cytosolic calcium.
  177. (1979). Factor VIII-related antigen in human blood platelets: localization and release by thrombin and collagen.
  178. (1991). Factor XI activation in a revised model of blood coagulation.
  179. (1997). Family history of coronary heart disease and hemostatic variables in middle-aged adults.
  180. (1986). Family history of coronary heart disease: is it an independent risk factor?
  181. (1999). Fast detection of tissue factor and tissue factor pathway inhibitor messenger RNA in endothelial cells and monocytes by sensitive reverse transcriptionpolymerase chain reaction.
  182. (2007). FatiGO +: a functional profiling tool for genomic data. Integration of functional annotation, regulatory motifs and interaction data with microarray experiments.
  183. (2000). FGFs, heparan sulfate and FGFRs: complex interactions essential for development.
  184. (1992). Fibrin gel network characteristics and coronary heart disease: relations to plasma fibrinogen concentration, acute phase protein, serum lipoproteins and coronary atherosclerosis.
  185. (1994). Fibrin in human plasma: gel architectures governed by rate and nature of fibrinogen activation.
  186. (2009). Fibrin network structure and clot mechanical properties are altered by incorporation of erythrocytes.
  187. (1998). Fibrinogen as a risk factor for coronary heart disease and mortality in middle-aged men and women. The Scottish Heart Health Study.
  188. (1987). Fibrinogen, cigarette smoking, and risk of cardiovascular disease: insights from the Framingham Study.
  189. (1995). Fibroblast growth factor-2 can mediate cell attachment by linking receptors and heparan sulfate proteoglycans on neighboring cells.
  190. (2007). Fibronectin-adherent monocytes express tissue factor and tissue factor pathway inhibitor whereas endotoxin-stimulated monocytes primarily express tissue factor: physiologic and pathologic implications.
  191. (2006). Flow cytometry-sorted non-viable endotoxin-treated human monocytes are strongly procoagulant.
  192. (2005). Forty-year mortality from cardiovascular diseases and their risk factors in men of the Italian rural areas of the Seven Countries Study.
  193. (2009). FOXO3adependent regulation of Pink1 (Park6) mediates survival signaling in response to cytokine deprivation.
  194. (2003). Fractalkine preferentially mediates arrest and migration of CD16+ monocytes.
  195. (2009). function during vascular development and disease.
  196. (1989). Functional tissue factor is entirely cell surface expressed on lipopolysaccharide-stimulated human blood monocytes and a constitutively tissue factor-producing neoplastic cell line.
  197. (2008). Further insight into the heparin-releasable and glycosylphosphatidylinositol-lipid--anchored forms of tissue factor pathway inhibitor.
  198. (2000). G20210A prothrombin gene polymorphism and extent of coronary disease.
  199. (1997). Gender differences in platelet GPIIb-IIIa activation.
  200. (2009). Gender differences in the cardiovascular effect of sex hormones.
  201. (2007). Gender-specific and menstrual cycle dependent differences in circulating microparticles.
  202. (2009). Gene expression analysis of human red blood cells.
  203. (1994). gene transcripts are expressed in human atherosclerotic lesions.
  204. (2005). Generation of tissue factor-rich microparticles in an ex vivo whole blood model.
  205. (2008). Genetic analysis of the role of the PI3K-Akt pathway in lipopolysaccharide-induced cytokine and tissue factor gene expression in monocytes/macrophages.
  206. (1995). Genetic regulation of fibrinogen.
  207. (1994). Genetic susceptibility to death from coronary heart disease in a study of twins.
  208. (2005). Genetic variations in the tissue factor gene are associated with clinical outcome in acute coronary syndrome and expression levels in human monocytes.
  209. (2004). Genetics of fibrin clot structure: a twin study.
  210. (2008). Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers.
  211. (2001). Glycoprotein VI but not alpha2beta1 integrin is essential for platelet interaction with collagen.
  212. (2003). Glycosyl phosphatidylinositol anchorage of tissue factor pathway inhibitor.
  213. (1985). Gray platelet syndrome: immunoelectron microscopic localization of fibrinogen and von Willebrand factor in platelets and megakaryocytes.
  214. (1986). Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study.
  215. (1998). Haemostatic risk factors for cardiovascular diseases.
  216. (1988). Heme oxygenase: function, multiplicity, regulatory mechanisms, and clinical applications.
  217. (1996). Hemostatic variables in the prediction of coronary risk: results of the 8 year follow-up of healthy men in the Munster Heart Study (PROCAM). Prospective Cardiovascular Munster Study.
  218. (1988). Heparin induces release of extrinsic coagulation pathway inhibitor (EPI).
  219. (2000). Heparin induces synthesis and secretion of tissue factor pathway inhibitor from endothelial cells in vitro.
  220. (2007). Heritability of clot formation, morphology, and lysis: the EuroCLOT study.
  221. (1994). Heterogeneity of plasma tissue factor pathway inhibitor.
  222. (2007). HIF-1-regulated glucose metabolism: a key to apoptosis resistance?
  223. (2003). Human cell-derived microparticles promote thrombus formation in vivo in a tissue factor-dependent manner.
  224. (1990). Human macrophage scavenger receptor primary structure, expression, and localisation in atherosclerotic lesions.
  225. (1977). Human platelet storage organelles. A review.
  226. (2007). Human platelets synthesize and express functional tissue factor.
  227. (1989). Identification and characterization of a novel monocyte subpopulation in human peripheral blood.
  228. (2007). Identification of a 2-stage platelet aggregation process mediating sheardependent thrombus formation.
  229. (2006). Identification of a novel human tissue factor splice variant that is upregulated in tumor cells.
  230. (1992). Identification of a specific glycoprotein ligand for P-selectin (CD62) on myeloid cells.
  231. (2005). Identification of novel vascular endothelialspecific genes by the microarray analysis of the zebrafish cloche mutants.
  232. (2009). Identification of NR4A2 as a transcriptional activator of IL-8 expression in human inflammatory arthritis.
  233. (2001). IEX-1, an immediate early gene, increases the rate of apoptosis in keratinocytes.
  234. (1998). IEX-1L, an apoptosis inhibitor involved in NF-kappaB-mediated cell survival.
  235. (2009). Impact of heterogeneity of human peripheral blood monocyte subsets on myocardial salvage in patients with primary acute myocardial infarction.
  236. (1997). Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice.
  237. (1985). In vitro stimulation of monocyte tissue factor activity by autologous platelets.
  238. (1958). In vitro thrombotic coagulation of the blood; a method for producing a thrombus.
  239. (1987). Incorporation of a circulating protein into megakaryocyte and platelet granules.
  240. (1994). Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques.
  241. (2002). Increased platelet binding to circulating monocytes in acute coronary syndromes.
  242. (1997). Induction of cytokine expression in leukocytes by binding of thrombin-stimulated platelets.
  243. (1999). Induction of inflammatory angiogenesis by monocyte chemoattractant protein-1.
  244. (2004). Induction of microparticle- and cell-associated intravascular tissue factor in human endotoxemia.
  245. (2008). Influence of coagulation factors and tissue factor concentration on the thrombin generation test in plasma.
  246. (2000). Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy.
  247. (2009). Inhibition of VEGF or TGF-{beta} signaling activates endothelium and increases leukocyte rolling.
  248. (1995). Integrin alpha 2 beta 1-independent activation of platelets by simple collagen-like peptides: collagen tertiary (triple-helical) and quaternary (polymeric) structures are sufficient alone for alpha 2 beta 1-independent platelet reactivity.
  249. (1998). Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A.
  250. (2002). Interactions between Eph kinases and ephrins provide a mechanism to support platelet aggregation once cell-tocell contact has occurred.
  251. (2001). Interleukin-8 administration enhances venous thrombosis resolution in a rat model.
  252. (2004). Internal carotid artery occlusive disease and polymorphisms of fractalkine receptor CX3CR1: a genetic risk factor.
  253. (2003). Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets.
  254. (2004). KLF2 Is a novel transcriptional regulator of endothelial proinflammatory activation.
  255. (2006). KLF2 provokes a gene expression pattern that establishes functional quiescent differentiation of the endothelium.
  256. (2005). Kruppel-like factor 2 (KLF2) regulates endothelial thrombotic function.
  257. (2000). Large scale gene expression analysis of cholesterolloaded macrophages.
  258. (2009). Leukocyte- and platelet-derived microparticles correlate with thrombus weight and tissue factor activity in an experimental mouse model of venous thrombosis.
  259. (2001). Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab.
  260. (1994). Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis.
  261. (1998). Lipid-protein interactions in blood coagulation.
  262. (2001). Lipopolysaccharide activation of the MEK-ERK1/2 pathway in human monocytic cells mediates tissue factor and tumor necrosis factor alpha expression by inducing Elk-1 phosphorylation and Egr-1 expression.
  263. (2002). Lipopolysaccharide recognition: CD14, TLRs and the LPS-activation cluster.
  264. (1995). Localization of protein disulfide isomerase to the external surface of the platelet plasma membrane.
  265. (2005). Long-term incubation with IL-4 and IL-10 oppositely modifies procoagulant activity of monocytes and modulates the surface expression of tissue factor and tissue factor pathway inhibitor.
  266. (2004). Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis.
  267. (2006). Macrophage inflammatory protein-2 promotes angiogenesis, cell migration, and tumor growth in hepatic metastasis.
  268. (2006). MAPK signal specificity: the right place at the right time.
  269. (2003). Markers of risk in young offspring with paternal history of myocardial infarction.
  270. (2004). Matrix management: assigning different roles for MMP-2 and MMP-9 in vascular remodeling.
  271. (1999). Measuring plasma fibrinogen to predict stroke and myocardial infarction: an update.
  272. (1998). Mechanism of tissue factor activation on cells.
  273. (1997). Mechanism of tissue factor activation on HL-60 cells.
  274. (1990). Megakaryocyte synthesis is the source of epidermal growth factor in human platelets.
  275. (1987). Menopause and the risk of coronary heart disease in women.
  276. (2003). Messenger RNA profiling of human platelets by microarray hybridization.
  277. (2008). Microparticle-mediated thrombin generation assay: increased activity in patients with recurrent thrombosis.
  278. (2006). Migratory fate and differentiation of blood monocyte subsets.
  279. (2007). Modulation of tissue factor-factor VIIa signaling by lipid rafts and caveolae.
  280. (1999). Molecular mechanism of thromboxane A(2)-induced platelet aggregation: Essential role for p2t(ac) and alpha(2a) receptors.
  281. (2000). Molecular mechanisms of platelet exocytosis:
  282. (2009). Monitoring thrombin generation: is addition of corn trypsin inhibitor needed? Thromb Haemost,
  283. (2007). Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques.
  284. (1994). Monocyte vesiculation is a possible mechanism for dissemination of membrane-associated procoagulant activities and adhesion molecules after stimulation by lipopolysaccharide.
  285. (2004). Monocytes and macrophages form branched cell columns in matrigel: implications for a role in neovascularization.
  286. (1997). Monocytes upregulate endothelial cell expression of tissue factor: a role for cell-cell contact and cross-talk.
  287. (1979). Mononuclear cell tissue factor: cell of origin and requirements for activation.
  288. (2006). Multidimensional local false discovery rate for microarray studies.
  289. (1994). Mutation in blood coagulation factor V associated with resistance to activated protein
  290. (2003). NAB2, a corepressor of EGR-1, inhibits vascular endothelial growth factormediated gene induction and angiogenic responses of endothelial cells.
  291. (1999). Neovascularization during venous thrombosis organization: a preliminary study.
  292. (2003). Neutrophil cathepsin G promotes prothrombinase and fibrin formation under flow conditions by activating fibrinogen-adherent platelets.
  293. (2002). New functions of neutrophils in the arthus reaction: expression of tissue factor, the clotting initiator, and fibrinolysis by elastase.
  294. (2001). Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis.
  295. (2005). Non-Smad TGF-beta signals.
  296. (2006). Nuclear receptors Nur77, Nurr1, and NOR-1 expressed in atherosclerotic lesion macrophages reduce lipid loading and inflammatory responses.
  297. (1958). Organisation and canalisation in arterial thrombosis.
  298. (1985). Organisation of experimental thrombosis by blood cells. Evidence of the transformation of mononuclear cells into myofibroblasts and endothelial cells. Virchows Arch A Pathol Anat Histopathol,
  299. (2002). Outside-in signals delivered by matrix metalloproteinase-1 regulate platelet function.
  300. (2001). Oxidized low density lipoprotein exposure alters the transcriptional response of macrophages to inflammatory stimulus.
  301. (2002). Oxidized lowdensity lipoprotein associates strongly with carboxy-terminal domain of tissue factor pathway inhibitor and reduces the catalytic activity of the protein.
  302. (2004). Oxidized phospholipids in oxidized low-density lipoprotein reduce the activity of tissue factor pathway inhibitor through association with its carboxyterminal region.
  303. (1994). P-selectin induces the expression of tissue factor on monocytes.
  304. (2002). P2X(1)-mediated activation of extracellular signal-regulated kinase 2 contributes to platelet secretion and aggregation induced by collagen.
  305. (1990). PADGEM-dependent adhesion of platelets to monocytes and neutrophils is mediated by a lineage-specific carbohydrate,
  306. (2003). Peripheral blood "endothelial progenitor cells" are derived from monocyte/macrophages and secrete angiogenic growth factors.
  307. (1996). Peripheral blood mononuclear phagocyte subpopulations as cellular markers in hypercholesterolemia.
  308. (2000). Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen.
  309. (1971). Phagocytosis of platelets by leukocytes in artificial thrombi and in platelet aggregates induced by adenosine diphosphate.
  310. (1990). Plasma fibrinogen and coronary risk factors: the Scottish Heart Health Study.
  311. (2005). Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis.
  312. (1995). Plasminogen activator inhibitor type 2 inhibits tumor necrosis factor alpha-induced apoptosis. Evidence for an alternate biological function.
  313. (2005). Platelet aggregation induces platelet aggregate stability via SLAM family receptor signaling.
  314. (1979). Platelet alpha granules contain a growth factor for fibroblasts.
  315. (1979). Platelet alpha-granule proteins: studies on release and subcellular localization.
  316. (2009). Platelet alpha-granules: basic biology and clinical correlates.
  317. (1997). Platelet and megakaryocyte dense granules contain glycoproteins Ib and IIb-IIIa.
  318. (2006). Platelet and monocyte activation by hyperglycemia and hyperinsulinemia in healthy subjects.
  319. (2008). Platelet chemokines in vascular disease.
  320. (2009). Platelet functions beyond hemostasis.
  321. (2005). Platelet heterogeneity: variation in coagulation complexes on platelet subpopulations.
  322. (2005). Platelet microparticles: a transcellular delivery system for RANTES promoting monocyte recruitment on endothelium.
  323. (2006). Platelet PECAM-1 inhibits thrombus formation in vivo.
  324. (1986). Platelet surface glycoproteins. Studies on resting and activated platelets and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory distress syndrome and cardiac surgery.
  325. (2001). Platelet-associated tissue factor contributes to the collagen-triggered activation of blood coagulation.
  326. (2005). Platelet-dependent thrombin generation assay for monitoring the efficacy of recombinant Factor VIIa.
  327. (1998). Platelet-derived interleukin-1 induces cytokine production, but not proliferation of human vascular smooth muscle cells.
  328. (1996). Platelet/polymorphonuclear leukocyte interaction in dynamic conditions: evidence of adhesion cascade and cross talk between P-selectin and the beta 2 integrin CD11b/CD18.
  329. (1999). Platelet/polymorphonuclear leukocyte interaction: P-selectin triggers protein-tyrosine phosphorylation-dependent CD11b/CD18 adhesion: role of PSGL-1 as a signaling molecule.
  330. (2003). Plateletmonocyte complex formation: effect of blocking PSGL-1 alone, and in combination with alphaIIbbeta3 and alphaMbeta2, in coronary stenting.
  331. (2008). Platelets and wound healing.
  332. (2000). Platelets induce alterations of chemotactic and adhesive properties of endothelial cells mediated through an interleukin-1-dependent mechanism. Implications for atherogenesis.
  333. (2004). Platelets of female mice are intrinsically more sensitive to agonists than are platelets of males.
  334. (2000). Platelets release their lysosomal content in vivo in humans upon activation.
  335. (1991). Platelets stimulate endothelial cells to synthesize type 1 plasminogen activator inhibitor. Evaluation of the role of transforming growth factor beta.
  336. (2004). Platelets: signaling cells in the immune continuum.
  337. (2006). Polymorphism in the tissue factor region is associated with basal but not endotoxin-induced tissue factor-mRNA levels in leukocytes.
  338. (1984). Potentiation by red blood cells of shearinduced platelet aggregation: relative importance of chemical and physical mechanisms.
  339. (2004). Prevalence of resistance against activated protein C resulting from factor V Leiden is significantly increased in myocardial infarction: investigation of 507 patients with myocardial infarction.
  340. (1997). Prevalence of the prothrombin gene variant (nt20210A) in venous thrombosis and arterial disease.
  341. (1998). Prevention of the influence of fibrin and alpha2-macroglobulin in the continuous measurement of the thrombin potential: implications for an endpoint determination of the optical density.
  342. (2008). Procoagulant membrane microparticles correlate with the severity of pulmonary arterial hypertension.
  343. (2006). Procoagulant microparticles: disrupting the vascular homeostasis equation? Arterioscler Thromb Vasc
  344. (2004). Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1.
  345. (1996). Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age.
  346. (1997). Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC)
  347. (2005). Protease-activated receptors in haemostasis, thrombosis and vascular biology.
  348. (2003). Protective autoimmunity against the enemy within: fighting glutamate toxicity.
  349. (1999). Proteins of the exocytotic core complex mediate platelet alpha-granule secretion. Roles of vesicleassociated membrane protein, SNAP-23, and syntaxin 4.
  350. (1998). Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular ischemic disease in young patients.
  351. (1989). Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma.
  352. (1991). Purification and properties of heparin-releasable lipoprotein-associated coagulation inhibitor.
  353. (1989). Purification of recombinant human tissue factor.
  354. (2002). Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse.
  355. (1986). Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1.
  356. (2001). Recruitment of labelled monocytes by experimental venous thrombi.
  357. (2003). Refinement of the association of serum C-reactive protein concentration and coronary heart disease risk by correction for within-subject variation over time: the MONICA Augsburg studies,
  358. (2007). Regulated surface expression and shedding support a dual role for semaphorin 4D in platelet responses to vascular injury.
  359. (2004). Regulation of innate and adaptive immune responses by MAP kinase phosphatase 5.
  360. (2001). Regulation of monocyte procoagulant activity in acute myocardial infarction: role of tissue factor and tissue factor pathway inhibitor-1.
  361. (2004). Regulation of NF-kappaB, Th activation, and autoinflammation by the forkhead transcription factor Foxo3a.
  362. (2001). Regulation of phosphatidylserine transbilayer redistribution by store-operated Ca2+ entry: role of actin cytoskeleton.
  363. (2008). Regulation of phospholipid asymmetry in the erythrocyte membrane.
  364. (2004). Regulation of T-cell death-associated gene 51 (TDAG51) expression in human T-cells.
  365. (2003). Regulation of tissue factor cytoplasmic domain phosphorylation by palmitoylation.
  366. (1989). Regulation of tissue factor gene expression in the monocyte procoagulant response to endotoxin.
  367. (1992). Relations between factor VIIa binding and expression of factor VIIa/tissue factor catalytic activity on cell surfaces.
  368. (2000). Release of active tissue factor by human arterial smooth muscle cells.
  369. (2003). Retinoids regulate survival and antigen presentation by immature dendritic cells.
  370. (2000). Reversible regulation of tissue factor-induced coagulation by glycosyl phosphatidylinositol-anchored tissue factor pathway inhibitor.
  371. (2004). Role for the Kunitz-3 domain of tissue factor pathway inhibitor-alpha in cell surface binding.
  372. (2000). Role of platelet P-selectin and CD40 ligand in the induction of monocytic tissue factor expression.
  373. (2004). Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation.
  374. (2003). Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity.
  375. (2000). Role of transforming growth factor beta in human disease.
  376. (2005). SDF-1alpha/CXCR4 axis is instrumental in neointimal hyperplasia and recruitment of smooth muscle progenitor cells.
  377. (1979). Secretable storage pools in platelets.
  378. (2007). Segregation of platelet aggregatory and procoagulant microdomains in thrombus formation: regulation by transient integrin activation.
  379. (2001). Sex difference in platelet aggregation detected by new aggregometry using light scattering.
  380. (1999). Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity.
  381. (2006). Signal-dependent splicing of tissue factor pre-mRNA modulates the thrombogenicity of human platelets.
  382. (2003). Smad-dependent and Smad-independent pathways in TGF-beta family signalling.
  383. (1987). Some long term effects of smoking on the haemostatic system: a report from the Caerphilly and Speedwell Collaborative Surveys.
  384. (2006). Sources of tissue factor.
  385. (1997). Specific accumulation of circulating monocytes and polymorphonuclear leukocytes on platelet thrombi in a vascular injury model.
  386. (2000). Structural basis of collagen recognition by integrin alpha2beta1.
  387. (2007). Structure of fibrin: impact on clot stability.
  388. (1991). Structure of the human lipoproteinassociated coagulation inhibitor gene. Intro/exon gene organization and localization of the gene to chromosome 2.
  389. (1984). Studies of hypercholesterolemia in the nonhuman primate. II. Fatty streak conversion to fibrous plaque.
  390. (1994). Studies of the mechanism for enhanced cell surface factor VIIa/tissue factor activation of factor X on fibroblast monolayers after their exposure to N-ethylmaleimide. Thromb Haemost,
  391. (2002). Subcellular distribution of 3 functional platelet SNARE proteins: human cellubrevin, SNAP-23, and syntaxin 2.
  392. (2004). Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response.
  393. (2006). Systems biology approaches identify ATF3 as a negative regulator of Toll-like receptor 4.
  394. (1999). TFPIbeta, a second product from the mouse tissue factor pathway inhibitor (TFPI) gene.
  395. (1999). The 20210 G-->A mutation in the 3'-untranslated region of the prothrombin gene and the risk for arterial thrombotic disease.
  396. (1995). The adhesion molecules used by monocytes for migration across endothelium include CD11a/CD18, CD11b/CD18, and VLA-4 on monocytes, and ICAM-1, VCAM-1, and other ligands on endothelium.
  397. (2007). The antithrombotic potential of selective blockade of talindependent integrin alpha IIb beta 3 (platelet GPIIb-IIIa) activation.
  398. (1988). The binding of factor Va to phospholipid vesicles.
  399. (2002). The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability.
  400. (2004). The chemokine system -- a major regulator of angiogenesis in health and disease.
  401. (2003). The contribution of glycoprotein VI to stable platelet adhesion and thrombus formation illustrated by targeted gene deletion.
  402. (1990). The contributions of Ca2+, phospholipids and tissuefactor apoprotein to the activation of human blood-coagulation factor X by activated factor VII.
  403. (1996). The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor.
  404. (1969). The dense bodies of human platelets: inherent electron opacity of the serotonin storage particles.
  405. (1963). The Early Stages of Thrombosis.
  406. (1990). The elastase-mediated pathway of fibrinolysis.
  407. (2005). The elasticity of an individual fibrin fiber in a clot.
  408. (1975). The endotoxin-induced coagulant activity of human monocytes.
  409. (2009). The gene encoding early growth response 2, a target of the transcription factor NFAT, is required for the development and maturation of natural killer T cells.
  410. (2008). The haemostatic role of tissue factor pathway inhibitor.
  411. (2001). The impact of calcification on the biomechanical stability of atherosclerotic plaques.
  412. (2008). The in vitro anticoagulant effects of danaparoid, fondaparinux, and lepirudin in children compared to adults.
  413. (2003). The influence of the src-family kinases, Lck and Fyn, on T cell differentiation, survival and activation.
  414. (1998). The interleukin 1 receptor: ligand interactions and signal transduction.
  415. (1966). The intravascular lifespan of monocytes.
  416. (2002). The junctional adhesion molecule 3 (JAM-3) on human platelets is a counterreceptor for the leukocyte integrin Mac-1.
  417. (2007). The local phospholipid environment modulates the activation of blood clotting.
  418. (2003). The low-frequency allele of the platelet collagen signaling receptor glycoprotein VI is associated with reduced functional responses and expression.
  419. (1996). The lysosomal granule membrane protein, LAMP-2, is also present in platelet dense granule membranes.
  420. (2005). The metabolic syndrome.
  421. (1988). The monocyte differentiation antigen, CD14, is anchored to the cell membrane by phosphatidylinositol linkage.
  422. (2005). The P-selectin, tissue factor, coagulation triad.
  423. (1998). The P2Y1 receptor is necessary for adenosine 5’-diphosphate-induced platelet aggregation.
  424. (2005). The platelet microparticle proteome.
  425. (2009). The platelet proteome.
  426. (2001). The platelet release reaction: granules' constituents, secretion and functions.
  427. (2002). The presence and release of tissue factor from human platelets.
  428. (2002). The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF.
  429. (1999). The protective effects of estrogen on the cardiovascular system.
  430. (1993). The protein CD63 is in platelet dense granules, is deficient in a patient with HermanskyPudlak syndrome, and appears identical to granulophysin.
  431. (2001). The role of factor XI in thrombin generation induced by low concentrations of tissue factor.
  432. (2006). The role of platelet adhesion receptor GPIbalpha far exceeds that of its main ligand, von Willebrand factor, in arterial thrombosis.
  433. (2001). The role of platelets in decrypting monocyte tissue factor.
  434. (1992). The safety and effect of topically applied recombinant basic fibroblast growth factor on the healing of chronic pressure sores.
  435. (2004). The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme.
  436. (2004). The TF-603A/G gene promoter polymorphism and circulating monocyte tissue factor gene expression in healthy volunteers.
  437. (2001). The tissue factor pathway in disseminated intravascular coagulation.
  438. (2008). The vessel wall and its interactions.
  439. (1999). The von Willebrand factor-glycoprotein Ib/V/IX interaction induces actin polymerization and cytoskeletal reorganization in rolling platelets and glycoprotein Ib/V/IX-transfected cells.
  440. (2004). Thrombin binding to GPIbalpha induces integrin alphaIIbbeta3 dependent platelet adhesion to fibrin in ex vivo flowing whole blood.
  441. (2007). Thrombin generation: a comparison of assays using platelet-poor and -rich plasma and whole blood samples from healthy controls and patients with a history of venous thromboembolism.
  442. (2006). Thrombospondin-1 controls vascular platelet recruitment and thrombus adherence in mice by protecting (sub)endothelial VWF from cleavage by ADAMTS13.
  443. (2003). Thrombospondin-1 mediates platelet adhesion at high shear via glycoprotein Ib (GPIb): an alternative/backup mechanism to von Willebrand factor.
  444. (2003). Thrombus formation: direct real-time observation and digital analysis of thrombus assembly in a living mouse by confocal and widefield intravital microscopy.
  445. (2007). Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications.
  446. (2009). Tissue factor +5466A>G polymorphism determines thrombin formation following vascular injury and thrombinlowering effects of simvastatin in patients with ischemic heart disease.
  447. (2007). Tissue factor activation: is disulfide bond switching a regulatory mechanism?
  448. (2005). Tissue factor activity in whole blood.
  449. (2006). Tissue factor and coagulation factor VII levels during acute myocardial infarction: association with genotype and adverse events.
  450. (2008). Tissue factor and IL8 production by P-selectin-dependent platelet-monocyte aggregates in whole blood involves phosphorylation of Lyn and is inhibited by IL10.
  451. (2003). Tissue factor and platelet glycoprotein Ib-alpha alleles are associated with age at first coronary bypass operation.
  452. (2007). Tissue factor coagulant function is enhanced by protein-disulfide isomerase independent of oxidoreductase activity.
  453. (1997). Tissue factor cytoplasmic domain peptide is multiply phosphorylated in vitro.
  454. (1999). Tissue factor de-encryption: ionophore treatment induces changes in tissue factor activity by phosphatidylserine-dependent and -independent mechanisms.
  455. (2002). Tissue factor deficiency causes cardiac fibrosis and left ventricular dysfunction.
  456. (2006). Tissue factor encryption.
  457. (2009). Tissue factor gene promoter haplotype associates with carotid intima-media thickness in subjects in cardiovascular risk prevention.
  458. (1999). Tissue factor is required for uterine hemostasis and maintenance of the placental labyrinth during gestation.
  459. (1991). Tissue factor mRNA in THP-1 monocytic cells is regulated at both transcriptional and posttranscriptional levels in response to lipopolysaccharide.
  460. (2000). Tissue factor on the loose.
  461. (2003). Tissue factor pathway inhibitor deficiency enhances neointimal proliferation and formation in a murine model of vascular remodelling.
  462. (2001). Tissue factor pathway inhibitor inhibits endothelial cell proliferation via association with the very low density lipoprotein receptor.
  463. (2005). Tissue factor pathway inhibitor on circulating microparticles in acute myocardial infarction.
  464. (1996). Tissue factor pathway inhibitor production by human mesangial cells in culture.
  465. (2004). Tissue factor promotor polymorphism -603 A/G is associated with myocardial infarction.
  466. (2007). Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer.
  467. (2009). Tissue factorinduced Thrombin Generation in the Fasting and Postprandial State among Elderly Survivors of Myocardial Infarction. Thromb Res.
  468. (2009). Tissue inhibitors of matrix metalloproteinases in platelets and megakaryocytes: a novel organization for these secreted proteins.
  469. (2005). Tissue-factorbearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation.
  470. (2003). Transcript profiling of human platelets using microarray and serial analysis of gene expression.
  471. (2003). Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth.
  472. (2006). Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression.
  473. (2009). Transcriptional profiling reveals developmental relationship and distinct biological functions of CD16+ and CD16- monocyte subsets.
  474. (2005). Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1.
  475. (1983). Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization.
  476. (2010). Uitterlinden, A.G.,Wellcome Trust Case Control Consortium, Aleksic,
  477. (1989). Uptake of plasma fibrinogen into the alpha granules of human megakaryocytes and platelets.
  478. (1996). Variability in platelet procoagulant activity in healthy volunteers.
  479. (2009). Vascular-directed tissue factor pathway inhibitor overexpression regulates plasma cholesterol and reduces atherosclerotic plaque development.
  480. (2009). VEGF autoregulates its proliferative and migratory ERK1/2 and p38 cascades by enhancing the expression of DUSP1 and DUSP5 phosphatases in endothelial cells.
  481. (1964). Waterfall Sequence for Intrinsic Blood Clotting.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.